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Dendritic Cell-Specific Intercellular Adhesion Molecule
3-Grabbing Nonintegrin/CD209 Is Abundant on Macrophages
in the Normal Human Lymph Node and Is Not Required for
Dendritic Cell Stimulation of the Mixed Leukocyte Reaction1
Angela Granelli-Piperno,* Alla Pritsker,† Maggi Pack,* Irina Shimeliovich,*
Jean-Francois Arrighi,‡ Chae Gyu Park,* Christine Trumpfheller,* Vincent Piguet,‡
Thomas M. Moran,† and Ralph M. Steinman2*
The C-type lectin dendritic cell-specific ICAM 3-grabbing nonintegrin (DC-SIGN)/CD209 efficiently binds several pathogens,
including HIV-1. DC-SIGN is expressed on monocyte-derived DCs in culture, and importantly, it is able to sequester HIV-1 within
cells and facilitate transmission of virus to CD4 T cells. To investigate DC-SIGN function, we have generated new mAbs. We
report in this study that these and prior anti-DC-SIGN mAbs primarily label macrophages in the medullary sinuses of nonin-
flamed human lymph node. In contrast, expression is not detected on most DCs in the T cell area, except for occasional cells. We
also noted that IL-4 alone can induce expression of DC-SIGN in CD14 monocytes and circulating blood DCs. However, blockade
of DC-SIGN with Abs and DC-SIGN small interfering RNA did not result in a major reduction in the capacity of these DCs to
transfer HIV to T cells, confirming significant DC-SIGN-independent mechanisms. The blocking approaches did reduce HIV-1
transmission by DC-SIGN-transfected cells by >90%. DC-SIGN blockade also did not reduce the ability of DCs to stimulate T
cell proliferation in the MLR. These results indicate that DC-SIGN has the potential to contribute to macrophage function in
normal human lymph node, and that DCs do not require DC-SIGN to transmit HIV or to initiate T cell responses. The Journal
of Immunology, 2005, 175: 4265–4273.
D endritic cell-specific ICAM 3-grabbing nonintegrin(DC-SIGN)3/CD209 is a C-type lectin expressed onDCs differentiated in vitro from CD14 cells cultured
with IL-4 and GM-CSF (1). Importantly, several microbial agents
bind to DC-SIGN, including viruses, bacteria, parasites, and yeast
(review in Ref. 2). This field began with the discovery that DC-
SIGN binds the HIV-1 gp120 envelope protein with high affinity
(3, 4). After uptake into monocyte-derived DCs and into DC-SIGN
transfectants, HIV-1 remains infectious for some time (5, 6) and is
transmitted to T cells at contact zones termed virological synapses
(7, 8). Binding of HIV-1 to DC-SIGN also can enhance direct
HIV-1 infection in cis (6, 9), but much of the research has focused
on the role of DC-SIGN as a receptor to explain the effective
sequestration and transmission of HIV-1 from DCs to T cells in
trans (4, 10–13). Nonetheless, the contribution of CD209 to
HIV-1 transmission has been documented primarily with Raji cells
transfected with DC-SIGN (4–6, 14). More recently DC-SIGN
expression has been nullified in DCs derived from CD34 pro-
genitor cells with small interfering RNA (siRNA), and this resulted
in a reduction of transmission of X4 tropic HIV in culture (15). For
monocyte-derived DCs, some studies have reported that HIV-1
transmission from DCs to T cells is mediated exclusively by DC-
SIGN (4, 5), whereas others report a relatively minor contribution
of DC-SIGN (6, 14, 16–18). Thus, the need for DC-SIGN in
HIV-1 transmission by monocyte-derived DCs is not clear.
In vivo expression of human DC-SIGN has been reported in
cells, possibly DCs, tonsil, the dermis of skin, and the subepithelial
region of cervix (1, 19–22). Studies of lymph nodes have been
limited, but have stressed the presence of scattered DC-SIGN-
bearing cells in the outer cortex, particularly in the subcapsular
sinuses and perifollicular regions (1, 19, 23, 24). In this paper we
have studied the in vivo expression and in vitro function of CD209.
To facilitate our studies, we first prepared a new panel of mAbs
using a recombinant vaccinia-DC-SIGN virus as an immunogen
and then compared these mAbs with existing reagents. We report
that CD209 in normal human lymph node is actually abundantly
expressed by macrophages in the lymph node medulla, rather than
DCs in the T cell area. Also, when we studied the blocking effects
of anti-CD209 Abs and siRNA in monocyte-derived DCs or DCs
from blood, our experiments did not reveal a major contribution of
DC SIGN to HIV-1 transmission by DCs, in contrast to DC-SIGN
transfectants or to the stimulating function of DCs in culture.
Materials and Methods
DC isolation
DCs were generated from the blood of normal donors, usually from buffy
coats purchased from the New York Blood Center. Monocyte-derived DCs
*Laboratory of Cellular Physiology and Immunology and Chris Browne Center for
Immunology and Immune Diseases, Rockefeller University, New York, NY 10021;
†Department of Microbiology, Mount Sinai School of Medicine, New York, NY
10029; and ‡Department of Dermatology and Venereology, University Hospital of
Geneva, Geneva, Switzerland
Received for publication April 20, 2005. Accepted for publication July 18, 2005.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by Direct Effect, Center for AIDS Research Grant
5P30AI42848-04 and National Institutes of Health Grants R01AI40045 and MO-
1RR00102 (to Rockefeller University General Clinical Research Center).
2 Address correspondence and reprint requests to Dr. Ralph M. Steinman, Laboratory
of Cellular Physiology and Immunology and Chris Browne Center for Immunology
and Immune Diseases, Rockefeller University, New York, NY 10021. E-mail address:
steinma@mail.rockefeller.edu
3 Abbreviations used in this paper: DC-SIGN, dendritic cell-specific ICAM 3-grab-
bing nonintegrin; MDCK, Madin-Darby canine kidney; MOI, multiplicity of infec-
tion; siRNA, small interfering RNA.
The Journal of Immunology
Copyright © 2005 by The American Association of Immunologists, Inc. 0022-1767/05/$02.00
 at Y
onsei M
edical Library on July 1, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
were prepared from PBMC as previously described (25, 26) with some
modification. Briefly, CD14 cells were obtained using anti-CD14 beads
(Miltenyi Biotec) and cultured for 6 days with IL-4 (R&D Systems; 10
ng/ml) and GM-CSF (Immunex; 100 IU/ml). The culture medium was
RPMI 1640 supplemented with 5% AB human serum (Gemini Bio-Prod-
ucts). Myeloid DCs were also isolated directly from Ficoll-Hypaque-en-
riched total blood mononuclear cells using the BDCA-1 isolation kit
(Miltenyi Biotec). BDCA1-positive cells represent 0.5–2% of the PBMCs.
The DCs were routinely phenotyped to determine contamination with
CD3-, CD19-, and CD16-expressing cells. The preparations contained
0.05% CD3 T cells and only traces of CD19 and CD16 cells.
Mice and immunizations
BALB/c mice, 6–8 wk old, were purchased from Charles River Breeding
Laboratories and were used within 8 wk. Four BALB/c mice were immu-
nized i.m. with 100 g of enhanced GFP plasmid N1 (BD Clontech) ex-
pressing the extracellular domain of DC-SIGN fused to GFP. Mice were
boosted three times with the same amount of plasmid 2 wk apart and were
bled to test for the level of specific Ab in sera. The sera were screened for
binding to Madin-Darby canine kidney (MDCK) cells transiently trans-
fected with pCAGGS expressing full-length DC-SIGN and DCs. Five days
before fusion, an immunized mouse was given 100 l of 107 PFU/ml
DC-SIGN/recombinant vaccinia virus i.p. Recombinant vaccinia virus
stocks expressing full-length DC-SIGN were generated, plaque purified,
and propagated in CV-1 African green monkey cells as previously de-
scribed (27). On the day of fusion, the mouse was bled, and the spleen was
removed for fusion. Fusion of splenocytes and SP2–0 cells were performed
by standard techniques previously described (28). On day 10, 100 l of
hybridoma supernatants were collected from each of 960 wells for
screening.
Screening of clones
Screening of supernatants was performed by immunostaining of MDCK
cells transiently transfected with DC-SIGN/pCAGGS mammalian expres-
sion vector. MDCK cells were transiently transfected in 96-well plates 24 h
before screening using Lipofectamine 2000 according to the manufactur-
er’s protocol (Invitrogen Life Technologies). The cells were fixed with 1%
formaldehyde/PBS, washed, and blocked with 1% BSA/PBS for 15 min at
room temperature. Supernatants from the wells were added to the MDCK
monolayer for 1 h at room temperature, and binding was identified with
anti-mouse IgG HRP-conjugated Ab, followed by the addition of the
3-amino-9-ethyl-carbazole substrate (Biomeda). The cells from the positive
wells were cloned by limiting dilution to generate single-cell clones. Su-
pernatants from the cloned wells were analyzed for binding to Raji cells
expressing DC-SIGN and human DCs by flow cytometry using a Cytomics
FC 500 (Beckman Coulter).
DC-SIGN-expressing cells
The generation of mammalian cells expressing type II transmembrane C-
type lectins was described previously (29). In brief, the extracellular do-
mains, a whole ectodomain, and a lectin domain of human DC-SIGN were
expressed as soluble protein fused to the C terminus of murine IgG Fc. The
cDNA constructs were inserted into the pCMV expression vector (BD
Clontech) and transfected onto Chinese hamster ovary cells. Expression of
the DC-SIGN domains was detected after cell permeabilization and FACS.
Chinese hamster ovary cells expressing mouse DC-SIGN and SIGN-R1
have been described previously (30). Raji-DC-SIGN and Hep-LSIGN were
provided by D. Littman (New York University, New York, NY) and J.
McKeating (Rockefeller University, New York, NY), respectively. The
expression of DC-SIGN and L-SIGN was monitored with specific mAbs.
The anti-DC-SIGN Abs, 120507 (DC-SIGN specific), 120612 (reacting
with DC-SIGN and L-SIGN), and 120604 (L-SIGN specific) were pur-
chased from R&D Systems, whereas AZN-D1 (4) and MR-1 (31) were
provided by Y. van Kooyk (Amsterdam, The Netherlands) and A. Corbi
(Madrid, Spain), respectively.
Lymph node tissue section staining
Surgical specimens of noninflamed human lymph nodes from the chest and
abdomen of cadaver transplant donors were provided by the New York
Organ Donor Network. The seven nodes showed no evidence of follicular
hyperplasia or infiltration with CD14 monocytes or CD32 granulocytes.
Tissues were obtained in protocols approved by the institutional review
boards of Weill Medical College, Cornell University, and Rockefeller Uni-
versity. Tissues were frozen and stored at80°C. Cryostat sections (6 m)
were air dried and fixed in acetone for 10 min at room temperature. Ags
were detected by immunofluorescence using anti-DC-SIGN mAbs (Table
I), anti-DEC-205 (clone MG 38-2) (32), anti-CD68 (DakoCytomation),
MMR (clone 3.29; provided by A. Lanzavecchia, Bellinzona, Switzerland),
and anti-CD11c (BD Biosciences). All primary mAbs were used at 1 g/
ml. Appropriate anti-mouse Alexa 488 or Alexa 546-conjugated isotype-
specific secondary Abs (Molecular Probes) were used at a dilution of 1/300
to reveal the primary mAbs. Sections were examined in a deconvolution
microscope (AX70; Olympus).
MLR
Immature or mature DCs were pretreated with anti-DC-SIGN Abs for 20
min at room temperature and then used to stimulate 105 T cells. The MLR
was conducted in round-bottom, 96-well microtest trays in 0.2 ml of RPMI
1640/5% human serum in the continued presence of the blocking mAb at
20 g/ml. Graded doses of DCs were added as indicated in Results. To
monitor the MLR, the T cells were labeled with CFSE (Molecular Probes).
Cells were stained with 2 M CFSE for 10 min at 37°C, followed by
quenching with FCS and three washes in complete medium. The MLR was
assessed by CFSE dilution on days 4–6 (see Results),
Sorting of lentivirus-transduced immature DCs and Raji
DC-SIGN transfectants
Immature DCs and Raji cells were transduced at a multiplicity of infection
(MOI) of 20 with lentiviral vectors expressing siRNA for DC-SIGN (si
DC-SIGN 11) or empty vector (15). After 48 h, cells were stained with
anti-DC-SIGN-PE and sorted for low DC-SIGN-expressing cells as shown
in Results. The cells were cultured for 24 h before use.
HIV-1 infection of immature DCs and Raji DC-SIGN
transfectants
Cells were infected with the BaL isolate, which we grew in PHA-stimu-
lated PBMCs. The virus was added at doses of 300–900 pg of p24 to105
target cells for 2 h at 37°C to immature DCs differentiated from monocytes
with GM-CSF and IL-4, DCs from fresh blood, or Raji cells stably trans-
fected with DC-SIGN. To study the blocking capacity of anti-DC-SIGN,
the indicated mAbs were added 20 min before infection and maintained
through the 2-h infection period. The cells were washed four times. To
determine the level of bound p24, cell lysates were obtained by adding
Table I. Specificity of the anti-DC-SIGN mAbsa
No. Clone Ig
DC-SIGN Abs Reactivity for:
Immature Raji Hep Hep Human DC-SIGN
Blot DC Raji DC-SIGN CD81 L-SIGN Lectin domain Ectodomain
1 9E9A8 IgG2a  No Yes No Yes No No Yes Yes
2 14E3G7 IgG2b  Yes Yes No Yes No Yes No Yes
3 13C7F4 IgG1  / Yes No Yes No Yes No Yes
4 19F7 IgG2b  Yes Yes No Yes No Yes No Yes
a Each Ab was assessed by FACS for their reactivity with DCs or transfected cells expressing DC-SIGN or L-SIGN. The clones were also tested for their ability to detect
DC-SIGN in cell lysates by Western blot.
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0.5% Triton. For studying HIV-1 transmission, 5 104 DC-SIGN-express-
ing cells were cultured with 105 activated T cells, and supernatants were
collected and assayed for p24 by ELISA (Coulter).
Results
Generation of anti-DC-SIGN mAbs with recombinant vaccinia-
DC-SIGN
To expand the availability of hybridomas secreting mAbs to DC-
SIGN/CD209, we used monocyte-derived DCs to immunize mice.
Although some investigators have succeeded in obtaining mAbs in
this way (1, 31), our mice did not generate good Ab responses
when tested with DC-SIGN transfectants even after four boosts.
Next, we immunized mice twice with DC-SIGN DNA and subse-
quently boosted with vaccinia expressing DC-SIGN. The sera from
immunized mice, but not the preimmune sera, were shown to react
with immature monocyte-derived DCs by FACS. The immune
spleen cells were fused with SP20 myeloma to generate hybrid-
omas, which again were screened by FACS for reactivity on im-
mature DCs. Twelve DC-SIGN-reactive mAbs were obtained and
subcloned, spanning most of the major mouse Ig isotypes, and four
were extensively characterized (Table I).
Each hybridoma was studied for the ability to stain DCs as well
as DC-SIGN and L-SIGN transfectants (and nontransfected paren-
tal cells as controls) by flow cytometry (Fig. 1A). Only one clone
recognized exclusively DC-SIGN (9E9A8, clone 1); all the others
reacted with both DC-SIGN and L-SIGN transfectants. This is not
surprising if one considers that DC-SIGN and L-SIGN are 73%
homologous and are identical in the membrane-proximal repeat
region of the ectodomain (33, 34). None of the Abs recognized
mouse SIGNR-1 or mouse DC-SIGN transfectants (not shown).
The hybridomas were examined for their capacity to detect DC-
SIGN by Western blotting (Fig. 1B); five of the 12 mAbs blotted
a major band at 50 kDa, corresponding to DC-SIGN, suggesting
that they recognize conformation-independent determinants. The
blots showed weaker bands at higher molecular masses which may
represent aggregates of DC-SIGN. Our immunization procedure,
DC-SIGN DNA prime, followed by vaccinia-DC SIGN boost,
therefore elicits a good immune response. We proceeded to use our
new anti-DC-SIGN reagents in parallel with other anti-DC-SIGN
mAbs provided by colleagues (AZN-D1 (4) and MR-1 (31)) and
commercial reagents purchased from R&D Systems.
DC-SIGN distribution in human lymph nodes
Although previous reports have identified scattered cells bearing
DC-SIGN in the outer cortex of human lymph nodes (see Discus-
sion), we surprisingly found that each of the mAbs to DC-SIGN in
our large panel produced strong staining of large cells in the med-
ullary sinuses (Fig. 2). Macrophages are known to be the predom-
inant large cell in the medullary sinuses, and in fact, all cells that
labeled for the macrophage markers, CD206 or macrophage man-
nose receptor and CD68, double labeled for DC-SIGN (Fig. 2).
This was the case with all anti-DC-SIGN Abs tested, e.g., MR-1,
AZN-D1, 507, and clone 1 from Table I (e.g., Fig. 2). To formally
prove that the new anti-DC-SIGN mAb stained similarly to pre-
vious DC-SIGN Abs, we performed double labeling for MR-1 and
found an overlap of the two labels (Fig. 3). Therefore, DC-SIGN
is expressed abundantly in the macrophages of the medullary si-
nuses of uninflamed human lymph nodes.
In the cortex, Abs to DC-SIGN did not show strong staining in
either B cell or T cell areas (Fig. 4, top row). The B cell regions
contained follicular DCs that stained with Abs to CD21 (Fig. 4, top
row), whereas the T cell regions contained DCs that stained with
Abs to DEC-205/CD205 and CD11c. Most DEC-205-positive DCs
were DC-SIGN negative (Fig. 4, middle row). Likewise, DC-SIGN
and CD11c primarily stained different cells: the former macro-
phages from the medulla, and the latter DCs in the cortex (Fig. 4,
lower row, left). We verified these findings with mAbs that react
with both DC-SIGN and L-SIGN. Again, these Abs did not stain
CD11c cells in the cortex (Fig. 4, lower row, middle), but did
stain medullary sinus macrophages (Fig. 4, lower row, right). In
the medulla, there were cells that stained with mAbs to L-SIGN/
DC-SIGN, but not with mAb to DC-SIGN only; these L-SIGN-
positive cells presumably are sinusoidal endothelium (Fig. 4, lower
row, right).
These data indicate that we could not readily identify cells in the
lymph node with the markers found in monocyte-derived DCs,
cells which have been the major object of research on DC-SIGN.
However, in two of our lymph nodes, we were able to identify foci
of cells with markers of monocyte-derived DCs, i.e., in addition to
DC-SIGN, the cells expressed CD11c and DEC-205 (Fig. 5).
These data indicate that DC-SIGN in the normal lymph node is
primarily expressed on medullary macrophages, rather than the
different types of DCs in the B and T cell areas, and that cells with
the phenotype of monocyte-derived DCs are a small fraction of the
DCs in lymph nodes.
DC-SIGN Abs inhibit HIV binding to Raji DC-SIGN
transfectants, but not DCs
We then assessed a panel of anti-DC-SIGN mAbs for their ability
to interfere with HIV-1 binding to Raji-DC-SIGN transfectants
and monocyte-derived immature DCs. Cells were incubated with
relatively low doses of virus (300–900 pg of p24/105 cells) for 2 h
at 37°C, washed, and lysed in 0.5% Triton. The amount of HIV-1
FIGURE 1. Reactivity of mAbs with DC-SIGN in
transfected cells and DCs. A, Reactivity of anti-
DC-SIGN mAb with DCs and transfectants expressing
full-length DC-SIGN or L-SIGN. B, Reactivity by im-
munoblot of anti-DC-SIGN mAb 2. The indicated cells
were lysates in RIPA buffer, equivalent to 3 105 cells.
After separation on SDS-PAGE, the lysates were blotted
with anti-DC-SIGN mAb 2.
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gag p24 in the lysates was then quantified by ELISA. HIV-1 bound
comparably to both types of cells in this assay (5–15 pg of p24),
and the degree of binding was dependent on the viral load (not
shown). In the case of the Raji transfectants, HIV-1 binding was
markedly (90–95%) blocked by a mixture of two different com-
mercially Abs (507 reacting with DC-SIGN and 612 reacting with
DC-SIGN/DC-L-SIGN), AZN-D1, and the panel of our new Abs
(Fig. 6, right panel). In contrast, these same anti-DC-SIGN mAbs
only slightly decreased HIV-1 binding to DCs studied in parallel
(Fig. 6, left panel). Therefore, HIV-1 binding to DC-SIGN trans-
fectants is DC-SIGN dependent, but a DC-SIGN independent
mechanism seems to predominate in monocyte-derived DCs, con-
firming previous reports with smaller numbers of mAb to DC-
SIGN (6, 14, 16, 17).
FIGURE 2. DC-SIGN staining is
restricted to macrophages in the med-
ullary sinuses (S) of lymph nodes.
Two-color staining is shown, with
red being the anti-DC-SIGN reagent,
and green the other markers. First
row, Clone 1 anti-DC-SIGN stains
macrophages in the sinuses of the
medulla and anti-CD3 stains T cells
in the medullary cords (C). Second
row, Clone 1 and anti-CD68 colabel
medullary macrophages. Third row,
Clone 1 and anti-macrophage man-
nose receptor (MMR) colabel macro-
phages in the lymph node medulla.
Fourth row, Double staining using a
commercial anti-DC-SIGN 507 and
anti-mannose receptor mAbs.
FIGURE 3. Identical staining by
clone 1 anti-DC-SIGN and another
established anti-DC-SIGN mAb.
Lymph node medulla sections were
double stained with our clone 1 and
the anti-DC-SIGN mAb MR-1.
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Effects of Abs and siRNA inhibition of DC-SIGN on
transmission of HIV-1 from DC-SIGN transfectants and DCs to
T cells
The anti-DC-SIGN mAbs were also tested for their capacity to
inhibit HIV-1 transmission from HIV-1-infected cells to activated T
cells. Cells preincubated with anti-DC-SIGN mAbs were exposed to
virus for 2 h and, after extensive washes, were cocultured with T cells.
Transfer of a productive infection to T cells was assessed in the cul-
ture supernatants by p24 ELISA. HIV-1 transmission from Raji-DC-
SIGN transfectants to T cells was completely blocked by the many
different anti-DC-SIGN and anti-L-SIGN Abs tested (Fig. 7A, right
panel). However, the anti-DC-SIGN mAbs even at high concentra-
tions (20 g/ml) had only a minimal effect on HIV-1 transfer from
monocyte-derived DC to T cells (Fig. 7A, left panel).
FIGURE 4. Immunostaining of
the lymph node cortex with anti-DC-
SIGN mAbs. First row, The lymph
node cortex is shown at 10 after
staining with anti-CD21 (green) to
define the B cell follicles (B) and the
unstained T cell region (T). Second
row, Images at higher magnification
within the T cell region reveal that
most DCs defined by staining with
anti-CD205 are DC-SIGN negative.
Third row, The left panel is a double
staining with our clone 10 (specific
for DC-SIGN and L-SIGN) and
CD11c; the middle panel is a double
staining with clone 612 (specific for
DC SIGN and L-SIGN) and
DEC205; the right panel shows a
double staining using anti-L-SIGN
specific mAb (604) with MR-1.
FIGURE 5. Immunostaining of
the lymph node cortex. Higher mag-
nification of the cortex where rare
fields can be found in which red DC-
SIGN-positive cells colabel with
CD11c and anti-CD205.
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The siRNA treatment via lentiviral vectors has recently been
used to down-regulate DC-SIGN expression in DCs derived from
CD34-positive progenitors (15). We repeated this approach with
Raji DC-SIGN transfectants and monocyte-derived DCs. Transfer
of HIV-1 was markedly reduced when Raji-DC-SIGN transfec-
tants were transduced with DC-SIGN siRNA vector, but not with
a control lentiviral vector (Fig. 7B, right). For monocyte-derived
DCs, DC-SIGN expression was also reduced, and we FACS-sorted
the fraction of cells in which DC-SIGN expression was compara-
ble to the isotype control mAb. In contrast to Raji DC-SIGN,
immature monocyte-derived DCs, when suppressed with the DC-
SIGN siRNA vector, were only marginally impaired in their ca-
pacity to transfer HIV-1 infection to T cells (Fig. 7B). These data
confirm that monocyte-derived DCs have a major alternative path-
way to DC-SIGN for transferring HIV-1 to competent T cells.
Induction of DC-SIGN on blood DC subsets does not affect HIV
transmission
We compared the expression of DC-SIGN on monocyte-derived
DCs, obtained in a standard way by culture with GM-CSF and
IL-4, to expression on the myeloid and plasmacytoid DC subsets
retrieved directly from blood with BDCA-1 (CD1c) and BDCA-4
(neuropilin)-positive selection (35). As reported, a high level of
DC-SIGN was found on DCs derived from CD14 monocytes, but
it is known that DC-SIGN expression is induced by IL-4 (31),
which is frequently used to differentiate monocytes into DCs. We
confirmed that low doses of IL-4 alone rapidly induced DC-SIGN
expression on CD14 monocytes (Fig. 8A, left). DC-SIGN was not
induced by GM-CSF, but GM-CSF and IL-4 together induced DC-
SIGN at levels higher than IL-4 alone. Moreover, circulating blood
myeloid DCs did not express DC-SIGN, but upon IL-4 treatment,
DC-SIGN expression was again induced (Fig. 8A, right). In con-
trast, DC-SIGN was not expressed by the plasmacytoid DCs and
was not induced after IL-4 treatment (not shown).
To examine the involvement of DC-SIGN in HIV-1 capture and
trans-enhancement by myeloid DCs from blood, we compared
DCs that were or were not cultured in IL-4 to induce DC-SIGN as
described above. After 48 h of IL-4 treatment to stimulate DC-
SIGN expression, the myeloid DCs were incubated with or without
anti-DC-SIGN mAb (AZN-D1), which has previously been shown
to block infection via DC-SIGN in monocyte-derived DCs and
Raji cells (4, 5). HIV-1 was then added for 2 h, the cells were
washed extensively and cocultured with CD4 T blasts, and the
kinetics of viral replication were assessed by gag p24 release (Fig.
8B). Equally robust infection was observed in the presence or the
absence of DC-SIGN induction or in the presence or the absence
of anti-DC SIGN-blocking Ab, which did block DC-SIGN-trans-
fected Raji cells studied in parallel (Fig. 8C). These results indicate
that myeloid DCs from blood can transmit HIV to T cells inde-
pendently from DC-SIGN.
DC-SIGN is not required for the response of T cells to DCs in
the MLR
The allogeneic MLR is used as a model to study the capacity of
DCs to initiate primary immune responses. Ab to DC-SIGN has
FIGURE 7. Effect of anti-DC-SIGN mAbs on HIV-1 transmission to T blasts. A, The indicated cells (left panel, immature DCs; right panel, Raji-DC-
SIGN) were incubated with anti-DC-SIGN mAbs as described in Fig. 6, and then infected with HIV-1 BaL in the continued presence of mAb. The cells
were washed four times, and 5  104 infected cells were cocultured with 105 T blasts. After 5 days, p24 secreted in the culture supernatants was quantified
by ELISA. Each symbol corresponds to an individual experiment. B, DC-SIGN-expressing cells were transduced with siRNA lentiviral vector or empty
vector at an MOI of 20, sorted for low DC-SIGN expression, and infected with HIV-1 before addition to T cells. The resulting cells were cocultured and
assayed as described above.
FIGURE 6. HIV-1 binding to DC-SIGN-expressing
cells. Cells were incubated with anti-DC-SIGN mAbs or
isotype control at 20 g/ml for 20 min at room temper-
ature and then infected with HIV-1 for 2 h at 37°C. Cells
were washed and lysed in 0.5% Triton. The amount of
p24 in the cell lysates was quantified by ELISA.
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been reported to block this response to some extent (1). We ana-
lyzed the effect of the panel of available anti-DC-SIGN mAbs
during an MLR, monitored by the dilution of CFSE as an index of
proliferation by CFSE-labeled CD3 T cells. The CFSE-labeled T
cells were cultured with several ratios of allogeneic and syngeneic
DCs that had been pretreated with anti-DC-SIGN mAbs, which
were maintained throughout the culture at 20 g/ml. The positive
control for blocking of the MLR was an anti-HLA-DR Ab (clone
L243), which profoundly inhibited T cell proliferation. However,
none of our new anti-DC-SIGN mAbs had an inhibitory effect in
all experiments similar to that shown in Fig. 9A. We then included
an additional approach in parallel, which was to knock down DC-
SIGN expression with a lentiviral vector expressing siRNA for
DC-SIGN. Immature monocyte-derived DCs were infected at an
MOI of 1:20 with siRNA DC-SIGN 11 (15), and after 48 h, the
low DC-SIGN-expressing cells (Fig. 9B) were sorted to enrich the
DC-SIGN-negative cells (Fig. 9C). These DC-SIGNlow DCs were
not altered in their MLR-stimulating activity, and in addition, the
other available sources of anti-DC-SIGN mAbs were unable to
block MLR stimulation (Fig. 9D). We failed to observe inhibition
over a range of DC to T cell ratios (1:10 to 1:100) and using both
immature monocyte-derived DCs (obtained by monocyte culture
with GM-CSF and IL-4) and mature DCs (obtained by treating the
immature DCs with a mixture of IL-1, IL-6, TNF-, and PGE2).
Taken together, our results do not show an involvement of DC-
SIGN in DC-induced T cell activation in the MLR.
Discussion
DC-SIGN/CD209 is a C-type lectin that is able to bind and trans-
mit HIV-1, as discovered by Geijtenbeek et al. (4), and it has been
implicated in the capacity of DCs to stimulate resting T cells (1).
To assess the function of DC-SIGN in the noninflamed human
lymph node, we have used a panel of anti-DC-SIGN mAbs, in-
cluding new reagents obtained by immunization with recombinant
vaccinia-DC-SIGN. Surprisingly, we found that DC-SIGN stain-
ing is primarily observed on macrophages throughout the medul-
lary sinuses, as manifest by strong colabeling for two molecules
that are abundant on macrophages, the CD68 lysosomal membrane
protein and the mannose receptor, and a lack of DC markers such
as CD205 and CD11c. In contrast, DCs in the T cell area of the
cortex express high levels of CD205 and CD11c, but were not
detectably stained with several new and previously available anti-
CD209 mAb. Our approaches cannot determine whether DC-SIGN
is not expressed at all, but only that the major depot of CD209 in
the human lymph node are macrophages in the medulla and not
DCs in the cortex. It will be important to learn how to isolate these
cells from the lymphoid tissues, but at this time we have not suc-
ceeded in releasing significant numbers of DCs or macrophages
with the very high levels of CD205 and CD209 that we observed
in sections. Other reports have called attention to the detection of
DC-SIGN on macrophages in lung and other sites (19, 36, 37), but
we report that in the noninflamed lymph node, DC-SIGN is abun-
dant on most macrophages in the medulla, but not in most DCs in
the T cell areas.
Our findings in sections are surprising relative to the previous
literature. Geijtenbeek et al. (1) identified some DC-SIGN cells
in the T cell areas. Lore et al. (23) reported DC-SIGN cells in the
parafollicular T cell-rich areas of lymph nodes from patients with
HIV and EBV infection, and that these cells were reduced in
healthy controls. Soilleux et al. (19) used a polyclonal anti-DC-
SIGN serum to examine adult and fetal tissues and reported some
cells with a dendritic morphology in the T cell areas and within
sinuses in the cortex. Tailleux et al. (38) studied DC-SIGN ex-
pression in lymph nodes from tuberculosis patients and reported
DC-SIGN cells within the granulomas and subcapsular sinuses.
Engering et al. (24) reported DC-SIGN cells in the outer cortex
in proximity to sinuses. While our study was under review, Krutzik
et al. (37) described how macrophages in leprosy lesions could
express DC-SIGN. Our paper, for the first time, reports the abun-
dance of this lectin in medullary macrophages in noninflamed
lymph nodes and its paucity on many T cell area DCs.
Our tissue section results indicate that many DCs in the T cell
areas lack the markers of monocyte-derived DCs, particularly high
expression of DC-SIGN/CD209 and mannose receptor/CD206. It
is possible that the equivalent of the cultured monocyte-derived
FIGURE 8. DC-SIGN expression is induced by IL-4 and is not required
for HIV-1 transmission by blood myeloid DCs. A, CD14 cells and
BDCA1 cells were cultured for 48 h with IL-4 (10 ng/ml), GM-CSF (100
IU/ml), or IL-4 and GM-CSF. Cells were stained with anti-DC-SIGN and
analyzed by FACS. B, Myeloid DCs were cultured for 48 h with or without
IL-4 (10 ng/ml), the latter to induce DC-SIGN expression. Part of the
cultures were incubated for 20 min with 20 g/ml anti-DC-SIGN mAb and
AZN-D1 and then infected with BaL for 2 h and washed. Infected DCs
(5  104) were cultured with 105 T blasts. Supernatants were collected at
different time points and analyzed for p24 secretion by ELISA. C, Raji
transfectants were studied in parallel.
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DCs only develops under select circumstances, e.g., during an in-
flammatory response or in special tissue niches. We and others (19,
31, 37, 39) found that cytokines such as IL-4, IL-13, and IL-15
quickly up-regulated DC-SIGN expression on monocytes, so that
cells with the phenotype of monocyte-derived DCs might accu-
mulate in situations such as parasite infection and allergy. The
reports of DC-SIGN cells in lymphatic sinuses, particularly in the
subcapsular region of lymph nodes, may also reflect migratory
monocyte-derived DCs responding to a stimulus in the periphery.
Within the T cell areas, we did detect small foci in which there
were CD11c- and DEC-205-positive DCs that coexpressed DC-
SIGN. However, most DCs in the T cell area had features shared
with the myeloid subset of DCs in blood, i.e., the cells expressed
CD11c and DEC-205/CD205, but lacked DC-SIGN and mannose
receptor. We propose that the finding of DC-SIGN-positive DCs in
the T cell areas represent situations where the equivalent of mono-
cyte-derived DCs are being generated in vivo, but that the major
reservoir of DC-SIGN in normal lymph node is the medullary
sinus macrophage rather than cortical DCs.
With the anti-DC-SIGN Abs we have generated and those al-
ready characterized, we also restudied the role of DC-SIGN as a
factor that participates in two types of DC-T cell interaction. All
the anti-DC-SIGN mAbs tested, in contrast to anti-HLA-DR, were
unable to inhibit DC-induced proliferation of resting T cells in the
MLR. These results differ from the initial conclusion that DC-
SIGN supports primary immune responses that arose from the ob-
servation that anti-DC-SIGN mAbs could reduce MLR stimulation
by 60% (1). However, we were unable to detect a block of the
MLR with a panel of anti-DC-SIGN mAbs even at limiting doses
of DCs and duration of MLR. We also looked at the contribution
of DC-SIGN to transmission of HIV by monocyte-derived DCs
and by blood DCs that had been induced to express DC-SIGN with
IL-4. We found that the mAbs to DC-SIGN did not impose a major
reduction on transmission of HIV by these DCs, whereas the same
mAbs led to a major 90% reduction of HIV transmission by
DC-SIGN-transfected Raji cells. In both the MLR and HIV trans-
mission assays, we additionally evaluated DCs in which DC-SIGN
expression had been dampened with siRNA, and again, no block-
ade was noted, even though this approach markedly reduced HIV
transmission from Raji DC-SIGN transfectants. These results are
consistent with several other reports that molecules other than DC-
SIGN can mediate virus transmission from DCs to T cells, using
monocyte-derived DCs (6, 14, 16–18, 40, 41). Likewise, there are
types of DCs that lack DC-SIGN, i.e., Langerhans cells and both
myeloid and plasmacytoid DCs in blood, that are able to transmit
HIV to T cells in vitro. Clearly, DC-SIGN represents an exciting
new mechanism by which pathogens are recognized by innate
cells, but DCs use additional mechanisms to transmit HIV, and we
suggest that macrophages within lymph nodes be considered in
pursuing the functions of DC-SIGN in vivo.
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